Business
Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells
Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells\nPR Newswire\nTEL-AVIV, Israel, August 28, 2017\n\n\n\nTEL-AVIV, Israel, August 28, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) (OTCQB: CNBX) today announced it received a very positive preliminary international patentability report from the PCT authorities regarding patent application PCT/IL2016/050471 finding all claims innovative and inventive.\n\n\n\nThis PCT report is a major step in the progress of the patent application which is now being launched into several major countries and territories. The company is securing its achievements through a very active and expanding patent portfolio. Other 2nd. Generation patent applications are in the pipeline and Cannabics Pharmaceuticals is aggressively expanding its patent estate as the company's R&D team continues to break new grounds.\n\nCannabics Pharmaceuticals has made unique developments in the application of medical cannabis to personalized medicine for cancer patients by providing a high throughput screening System (HTS) able to identify the antitumor effect of cannabis strains for individual patients under treatment. \n\nDr. Eyal Ballan, CTO of Cannabics Pharmaceuticals noted, \"As we progress in the field of cannabinoids and cancer we find the unmet need of personalizing cannabis medicine and fortunate to carry out this mission\". \n\nAbout Cannabics Pharmaceuticals Inc.\n\nCannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid f...